This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Federman & Sherwood Investigates Peregrine Pharmaceuticals, Inc. For Possible Securities Fraud

The law firm of Federman & Sherwood has initiated an investigation into California-based Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (“Peregrine”) with respect to possible breaches of fiduciary duty by the company’s officers and directors, as well as violations of state and federal securities laws, when the Company failed to disclose to its investors the problems it was facing with its double-blind placebo-controlled Phase II trial of its drug Bavituximab in patients with second-line, non-small cell lung cancer, as well as fully disclosing the Company’s true financial condition when Peregrine announced it had defaulted on a $30 million loan agreement it had just entered into on August 30, 2012.

Federman & Sherwood is investigating whether: (1) the information being provided to Peregrine shareholders about the clinical trials surrounding Bavituximab during the class period was false and/or misleading at the time such information was being disseminated; (2) whether the Company knew that the clinical study with Bavituximab was not going well and failed to properly and timely notify its shareholders of same; and, (3) whether the Company properly disclosed its true financial condition during the Class Period.

If you currently own common stock in Peregrine Pharmaceuticals, Inc. and purchased your shares between September 7, 2012 and September 24, 2012; have information to assist in our investigation; or, have any questions or concerns regarding this notice or preservation of your rights, please contact William B. Federman at wbf@federmanlaw.com. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs